News | Molecular Imaging | July 09, 2015

Blue Earth Diagnostics Granted U.S., European Orphan Drug Designation for F-18 Fluciclovine

PET agent is used to diagnose gliomas in brain and central nervous system

Blue Earth Diagnostics, fluciclovine, 18F, orphan drug designation, PET

July 9, 2015 - Blue Earth Diagnostics Ltd (BED) announced it has received both U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Orphan Drug Designation (ODD) for fluciclovine (18F) in the diagnosis of glioma. Fluciclovine is an investigational positron emission tomography (PET) radiopharmaceutical based on a synthetic amino acid, which appears to be preferentially taken up in a number of cancer indications, including in prostate cancer and brain tumors.

Gliomas make up about 30 percent of all brain and central nervous system tumors and 80 percent of all malignant brain tumors. The symptoms, prognosis, and treatment of a malignant glioma depend on the person's age, the exact type of tumor and the location of the tumour - which often penetrates deep into the brain. PET scan pictures show biological function and are complimentary with computed tomography (CT) scans and magnetic resonance imaging (MRI). Blue Earth Diagnostics plans to investigate the role of fluciclovine (18F) PET in evaluating the spread of both high and low grade glioma within the brains of affected patients.

Jeffrey Olson, M.D., neurosurgeon at Emory University, Atlanta, commented, "Although diagnosis of tumors of the brain with standard surgical, histologic and imaging techniques - such as CT and MRI - is accurate and well established, definitive staging and management of these diseases later in their course is in need of improvement. Imaging based on alternative mechanisms, such as PET with fluciclovine, offer the possibility of accurate diagnosis with the possibility of faster evaluation of therapeutic response. The addition of novel PET data to MRI, for example, may give treating physicians the confidence to continue treatment or justification to move on to an alternative therapy."

For more information: www.blueearthdiagnostics.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a
SIR-Spheres Y-90 resin

SIR-Spheres Y-90 resin microspheres are released into the hepatic artery.

News | Nuclear Imaging | February 14, 2020
February 14, 2020 —  ...
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Nuclear imaging of the spine shown on Philips Healthcare BrightView XCT

Image courtesy of Philips Healthcare

News | Nuclear Imaging | January 27, 2020
January 27, 2020 — According to the new market research report "...